Table 3 Clinical characteristics of patients with de novo metastatic NPC according to risk after PCT
Low-risk patients (n = 208) | High-risk patients (n = 294) | |||||
|---|---|---|---|---|---|---|
Characteristic | LRRT | Non-LRRT | P-value | LRRT | Non-LRRT | P-value |
Total | 165 | 43 | 150 | 144 | ||
Gender | ||||||
Male | 134 (81.2%) | 34 (79.1%) | 0.828 | 128 (85.3%) | 121 (84.0%) | 0.871 |
Female | 31 (18.8%) | 9 (20.9%) | 22 (14.7%) | 23 (16.0%) | ||
Age (years) | ||||||
≤ 47 | 94 (57.0%) | 19 (44.2%) | 0.169 | 77 (51.3%) | 71 (49.3%) | 0.816 |
> 47 | 71 (43.0%) | 24 (55.8%) | 73 (48.7%) | 73 (50.7%) | ||
T stage | ||||||
T1 | 5 (3.0%) | 0 (0.0%) | 0.495* | 6 (4.0%) | 10 (6.9%) | 0.458 |
T2 | 22 (13.3%) | 4 (9.3%) | 22 (14.7%) | 15 (10.4%) | ||
T3 | 83 (50.3%) | 20 (46.5%) | 71 (47.3%) | 74 (51.4%) | ||
T4 | 55 (33.3%) | 19 (44.2%) | 51 (34.0%) | 45 (31.3%) | ||
N stage | ||||||
N0 | 9 (5.5%) | 0 (0.0%) | 0.362 | 4 (2.7%) | 3 (2.1%) | 0.452* |
N1 | 33 (20.0%) | 8 (18.6%) | 29 (19.3%) | 19 (13.2%) | ||
N2 | 73 (44.2%) | 18 (41.9%) | 52 (34.7%) | 59 (41.0%) | ||
N3 | 50 (30.3%) | 17 (39.5%) | 65 (43.8%) | 63 (43.8%) | ||
Metastatic sites | ||||||
Bone | 99 (60.0%) | 13 (30.2%) | < 0.001* | 64 (42.7%) | 50 (34.7%) | 0.006 |
Lung | 25(%15.2) | 13 (30.2%) | 15 (10.0%) | 11 (7.6%) | ||
Liver | 9 (5.5%) | 6 (14.0%) | 14 (9.3%) | 20 (13.9%) | ||
Distant nodal | 20 (12.1%) | 0 (0.0%) | 13 (8.7%) | 2 (1.4%) | ||
Multiple sites | 12 (7.3%) | 11 (25.6%) | 44 (29.3%) | 61 (42.4%) | ||
PCT regimens | ||||||
TPF | 55 (33.3%) | 10 (23.3%) | 0.021 | 33 (22.0%) | 32 (22.2%) | 0.180 |
TP | 46 (27.9%) | 7 (16.3%) | 39 (26.0%) | 29 (20.1%) | ||
PF | 33 (20.0%) | 16 (37.2%) | 40 (26.7%) | 42 (29.2%) | ||
GP | 4 (2.4%) | 4 (9.3%) | 5 (3.3%) | 14 (9.7%) | ||
Others | 27 (16.4%) | 6 (14.0%) | 33 (22.0%) | 27 (18.8%) | ||